ArticleFrontiers in genetics2026
Construction and validation of a prognostic model for lung adenocarcinoma based on necrotic cell death triggered by sodium overload-related coexpressed genes.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to explore the prognostic significance of necrotic cell death triggered by sodium overload (NECSO)-related genes in lung adenocarcinoma (LUAD) and construct a prognostic model with high predictive efficiency. The findings will enable a precise stratification of the prognostic risk of patients with LUAD. Analysis of the constructed prognostic model, immune cell infiltration, and tumor mutational burden (TMB) will facilitate the development of individualized precision medical protocols. Methods: Based on the LUAD data obtained from TCGA and GEO databases, a prognostic prediction model for LUAD containing 15 key genes (including arginyl aminopeptidase like 1 [RNPEPL1] and beta-1,3-N-acetylglucosaminyltransferase 3 [B3GNT3]) coexpressing with the key NECSO gene, TRPM4, was established. Results: Risk score was identified as an independent prognostic factor. High-risk patients had the following characteristics: high frequency of mutations in TP53 and TTN genes, high TMB, high number of immunosuppressive cells with impaired immune cell function, and abnormally active metabolism. Nomograms developed by integrating clinical features and risk scores displayed high predictability. Discussion: The findings provide new molecular markers and potential therapeutic targets for the prognosis of LUAD and lay a theoretical foundation for the development of therapeutic approaches targeting the NECSO mechanism in patients with LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.